Pilot study of minocycline in relapsing-remitting multiple sclerosis

Yunyan Zhang, Luanne M. Metz, V. Wee Yong, Robert B. Bell, Michael Yeung, David G. Patry, Joseph Ross Mitchell

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Current multiple sclerosis (MS) treatment is only partially effective and not all patients respond well. The goal in this study was to evaluate minocycline for its safety, tolerability, and MRI impact as a potential therapy over 36 months after a three month run-in in ten relapsing-remitting (RR) MS patients. Methods: Clinical assessments were at three month intervals until six months, then at six month intervals. Three Tesla MRI was performed monthly during the run-in and first six months of treatment, then at 12, 24, and 36 months. Results: Treatment was safe and well tolerated. Annualized relapse rate was 1.2 during the run-in and 0.25 during treatment. The proportion of active scans was lower during the first six months of treatment (5.6%, p<0.001) and during the extension (8.7%, p= 0.002) than during the run-in (47.5%). Consistent with these outcomes, mean T2 lesion volume remained stable over three years and percent brain volume change was reduced during year three (-0.37%) of minocycline treatment. Conclusions: This trial is limited by small sample and no control group but suggests that minocycline is safe and potentially beneficial in RRMS. This supports further investigation of its efficacy.

Original languageEnglish (US)
Pages (from-to)185-191
Number of pages7
JournalCanadian Journal of Neurological Sciences
Volume35
Issue number2
StatePublished - May 2008
Externally publishedYes

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Minocycline
Therapeutics
Multiple Sclerosis
Safety
Recurrence
Control Groups
Brain

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Zhang, Y., Metz, L. M., Yong, V. W., Bell, R. B., Yeung, M., Patry, D. G., & Mitchell, J. R. (2008). Pilot study of minocycline in relapsing-remitting multiple sclerosis. Canadian Journal of Neurological Sciences, 35(2), 185-191.

Pilot study of minocycline in relapsing-remitting multiple sclerosis. / Zhang, Yunyan; Metz, Luanne M.; Yong, V. Wee; Bell, Robert B.; Yeung, Michael; Patry, David G.; Mitchell, Joseph Ross.

In: Canadian Journal of Neurological Sciences, Vol. 35, No. 2, 05.2008, p. 185-191.

Research output: Contribution to journalArticle

Zhang, Y, Metz, LM, Yong, VW, Bell, RB, Yeung, M, Patry, DG & Mitchell, JR 2008, 'Pilot study of minocycline in relapsing-remitting multiple sclerosis', Canadian Journal of Neurological Sciences, vol. 35, no. 2, pp. 185-191.
Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Canadian Journal of Neurological Sciences. 2008 May;35(2):185-191.
Zhang, Yunyan ; Metz, Luanne M. ; Yong, V. Wee ; Bell, Robert B. ; Yeung, Michael ; Patry, David G. ; Mitchell, Joseph Ross. / Pilot study of minocycline in relapsing-remitting multiple sclerosis. In: Canadian Journal of Neurological Sciences. 2008 ; Vol. 35, No. 2. pp. 185-191.
@article{a93ed1dae4094cd698549dfe792b9d90,
title = "Pilot study of minocycline in relapsing-remitting multiple sclerosis",
abstract = "Background: Current multiple sclerosis (MS) treatment is only partially effective and not all patients respond well. The goal in this study was to evaluate minocycline for its safety, tolerability, and MRI impact as a potential therapy over 36 months after a three month run-in in ten relapsing-remitting (RR) MS patients. Methods: Clinical assessments were at three month intervals until six months, then at six month intervals. Three Tesla MRI was performed monthly during the run-in and first six months of treatment, then at 12, 24, and 36 months. Results: Treatment was safe and well tolerated. Annualized relapse rate was 1.2 during the run-in and 0.25 during treatment. The proportion of active scans was lower during the first six months of treatment (5.6{\%}, p<0.001) and during the extension (8.7{\%}, p= 0.002) than during the run-in (47.5{\%}). Consistent with these outcomes, mean T2 lesion volume remained stable over three years and percent brain volume change was reduced during year three (-0.37{\%}) of minocycline treatment. Conclusions: This trial is limited by small sample and no control group but suggests that minocycline is safe and potentially beneficial in RRMS. This supports further investigation of its efficacy.",
author = "Yunyan Zhang and Metz, {Luanne M.} and Yong, {V. Wee} and Bell, {Robert B.} and Michael Yeung and Patry, {David G.} and Mitchell, {Joseph Ross}",
year = "2008",
month = "5",
language = "English (US)",
volume = "35",
pages = "185--191",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "2",

}

TY - JOUR

T1 - Pilot study of minocycline in relapsing-remitting multiple sclerosis

AU - Zhang, Yunyan

AU - Metz, Luanne M.

AU - Yong, V. Wee

AU - Bell, Robert B.

AU - Yeung, Michael

AU - Patry, David G.

AU - Mitchell, Joseph Ross

PY - 2008/5

Y1 - 2008/5

N2 - Background: Current multiple sclerosis (MS) treatment is only partially effective and not all patients respond well. The goal in this study was to evaluate minocycline for its safety, tolerability, and MRI impact as a potential therapy over 36 months after a three month run-in in ten relapsing-remitting (RR) MS patients. Methods: Clinical assessments were at three month intervals until six months, then at six month intervals. Three Tesla MRI was performed monthly during the run-in and first six months of treatment, then at 12, 24, and 36 months. Results: Treatment was safe and well tolerated. Annualized relapse rate was 1.2 during the run-in and 0.25 during treatment. The proportion of active scans was lower during the first six months of treatment (5.6%, p<0.001) and during the extension (8.7%, p= 0.002) than during the run-in (47.5%). Consistent with these outcomes, mean T2 lesion volume remained stable over three years and percent brain volume change was reduced during year three (-0.37%) of minocycline treatment. Conclusions: This trial is limited by small sample and no control group but suggests that minocycline is safe and potentially beneficial in RRMS. This supports further investigation of its efficacy.

AB - Background: Current multiple sclerosis (MS) treatment is only partially effective and not all patients respond well. The goal in this study was to evaluate minocycline for its safety, tolerability, and MRI impact as a potential therapy over 36 months after a three month run-in in ten relapsing-remitting (RR) MS patients. Methods: Clinical assessments were at three month intervals until six months, then at six month intervals. Three Tesla MRI was performed monthly during the run-in and first six months of treatment, then at 12, 24, and 36 months. Results: Treatment was safe and well tolerated. Annualized relapse rate was 1.2 during the run-in and 0.25 during treatment. The proportion of active scans was lower during the first six months of treatment (5.6%, p<0.001) and during the extension (8.7%, p= 0.002) than during the run-in (47.5%). Consistent with these outcomes, mean T2 lesion volume remained stable over three years and percent brain volume change was reduced during year three (-0.37%) of minocycline treatment. Conclusions: This trial is limited by small sample and no control group but suggests that minocycline is safe and potentially beneficial in RRMS. This supports further investigation of its efficacy.

UR - http://www.scopus.com/inward/record.url?scp=45149091084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45149091084&partnerID=8YFLogxK

M3 - Article

C2 - 18574932

AN - SCOPUS:45149091084

VL - 35

SP - 185

EP - 191

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 2

ER -